Open AccessEfficacy and Safety of Apatinib for Elderly Patients with Advanced or Metastatic Gastric Cancer After Failure of at Least First-Line Chemotherapy: A Multi-Center, Single-Arm, Phase II Study
Author(s) -
Dengfeng Ren,
Guoxiu Wang,
Yu Zhang,
Jie Kan,
Qiuxia Dong,
Jing Zhao,
Faxiang Ji,
Hao Li,
Ying Luo,
Ming-Zhe Lin,
Guoyuan Li,
Zhibo Liu,
Xinfu Ma,
Qijing Guo,
Fuxing Zhao,
Guoshuang Shen,
Jiuda Zhao
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s322710
Subject(s) - medicine , apatinib , cancer , clinical endpoint , progression free survival , phases of clinical research , leukopenia , chemotherapy , single center , surgery , adverse effect , gastroenterology , oncology , clinical trial
Apatinib improves progression-free survival and overall survival with an acceptable safety profile in Chinese patients with chemotherapy-refractory advanced or metastatic gastric cancer. However, the efficacy and safety of apatinib are unclear for elderly patients. This study was undertaken to prospectively investigate the efficacy and safety of apatinib for elderly patients with unresectable advanced or metastatic gastric cancer, who experienced progression to at least one lines of chemotherapy.